Interim report Q3 2024
Business Highlights during and after the third quarter of 2024
- Curasight designates brain cancer as initial indication for uTREAT
- Clinical Phase II trial of uPAR-PET in brain cancer patients
- Strong demand for rights issue resulted in heavy oversubscription
- Continued business development activities with industry players
Copenhagen, Denmark, 21 November 2024 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) hereby publishes the interim report for the third quarter, and the first nine months, 2024. The interim report is available as an attached file to this release and on the Company’s website. Below is a summary of the report.
Curasight's CEO Ulrich Krasilnikoff comments:
"Throughout the first three quarters of 2024, we have built upon last year's successes, fortifying Curasight's role in radiopharmaceuticals. Key milestones include enrolling our first patient in the Phase II trial of uTRACE for prostate cancer and furthering our partnership with Curium, where we received a second milestone payment under the collaboration. Additionally, we announced a capital raise designed to enhance our financial position, and extending our cash runway well into the latter half of 2025."
Q3 (2024-07-01 - 2024-09-30)
- Gross loss amounted to kDKK -6,135 (kDKK -6,551)
- Operating loss amounted to kDKK -8,099 (kDKK -8,465)
- Loss before tax amounted to kDKK -8,523 (kDKK -8,484)
- Loss for the period amounted to kDKK -7,148 (kDKK -6,618)
- Total assets amounted to kDKK 25,778 (kDKK 41,913)
- Equity ratio amounted to 51.6% (90.1%)
- Earnings per share amounted to DKK -0.35 (DKK -0.33)
Q1-Q3 (2024-01-01 - 2024-09-30)
- Gross loss amounted to kDKK -22,521 (kDKK -20,236)
- Operating loss amounted to kDKK -28,443 (kDKK -25,307)
- Loss before tax amounted to kDKK -30,002 (kDKK -25,328)
- Loss for the period amounted to kDKK -25,877 (kDKK -19,756)
- Total assets amounted to kDKK 25,778 (kDKK 41,913)
- Equity ratio amounted to 51.6% (90.1%)
- Earnings per share amounted to DKK -1.25 (DKK -0.99)
Numbers in parenthesis are the numbers from the same period in 2023.
For more information regarding Curasight, please contact:
Ulrich Krasilnikoff, CEO
Phone: +45 22 83 01 60
E-mail: uk@curasight.com
www.curasight.com
Curasight is a clinical development company based in Copenhagen, Denmark. The Company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging (uTRACE®) and Radioligand Therapy (uTREAT®) Theranostic Platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology is expected to improve diagnosis and provide more gentle and efficient treatment of multiple cancer types.
https://news.cision.com/curasight/r/interim-report-q3-2024%2Cc4069505
Curasight - Interim Report Q3 2024